Business Description
EQL Pharma AB
ISIN : SE0005497732
Total Employee Number:
23Compare
Compare
Traded in other countries / regions
EQL.Sweden7JK.Germany IPO Date
2024-07-04Description
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.18 | |||||
Equity-to-Asset | 0.31 | |||||
Debt-to-Equity | 1.82 | |||||
Debt-to-EBITDA | 9.96 | |||||
Interest Coverage | 1.6 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.69 | |||||
Beneish M-Score | -2.6 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 17.7 | |||||
3-Year EBITDA Growth Rate | 4.9 | |||||
3-Year EPS without NRI Growth Rate | -26.1 | |||||
3-Year Book Growth Rate | 19.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.26 | |||||
9-Day RSI | 35.02 | |||||
14-Day RSI | 33.21 | |||||
3-1 Month Momentum % | -57.55 | |||||
6-1 Month Momentum % | -60.56 | |||||
12-1 Month Momentum % | -74.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.92 | |||||
Quick Ratio | 0.97 | |||||
Cash Ratio | 0.41 | |||||
Days Inventory | 258.71 | |||||
Days Sales Outstanding | 86.77 | |||||
Days Payable | 91.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.5 | |||||
Shareholder Yield % | -39.38 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 37.64 | |||||
Operating Margin % | 11.25 | |||||
Net Margin % | 2.9 | |||||
EBITDA Margin % | 11.25 | |||||
FCF Margin % | -9.1 | |||||
OCF Margin % | 6.56 | |||||
ROE % | 5.02 | |||||
ROA % | 1.53 | |||||
ROIC % | 4.97 | |||||
3-Year ROIIC % | 0.19 | |||||
ROC (Joel Greenblatt) % | 21.23 | |||||
ROCE % | 7.86 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 55.12 | |||||
PE Ratio without NRI | 55.12 | |||||
Shiller PE Ratio | 36.04 | |||||
PEG Ratio | 2.15 | |||||
PS Ratio | 1.61 | |||||
PB Ratio | 2.56 | |||||
Price-to-Operating-Cash-Flow | 24.55 | |||||
EV-to-EBIT | 22.22 | |||||
EV-to-EBITDA | 22.22 | |||||
EV-to-Revenue | 2.5 | |||||
EV-to-FCF | -27.83 | |||||
Price-to-DCF (Earnings Based) | 4.07 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.2 | |||||
Earnings Yield (Greenblatt) % | 4.5 | |||||
FCF Yield % | -5.76 | |||||
Forward Rate of Return (Yacktman) % | 10.32 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
EQL Pharma AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 432.662 | ||
| EPS (TTM) (kr) | 0.42 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 52.32 | ||
| 14-Day RSI | 33.21 | ||
| 14-Day ATR (kr) | 1.61821 | ||
| 20-Day SMA (kr) | 24.3 | ||
| 12-1 Month Momentum % | -74.59 | ||
| 52-Week Range (kr) | 21.35 - 108.8 | ||
| Shares Outstanding (Mil) | 29.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
EQL Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
EQL Pharma AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2026-11-05 | In 125 days | ||
| General meeting for 2026 | 2026-08-21 16:00 | In 50 days | ||
| First quarter earnings conference call for 2027 | 2026-08-07 10:00 | In 36 days | ||
| First quarter earnings results for 2027 | 2026-08-07 | In 35 days | ||
| Annual report for 2026 | 2026-07-28 | In 25 days | ||
| Fourth quarter earnings results for 2026 | 2026-05-08 | 53.20 (+7.91%) | ||
| Third quarter earnings results for 2026 | 2026-02-03 | 64.30 (+6.99%) | ||
| Second quarter earnings results for 2026 | 2025-11-05 | 61.30 (-0.81%) | ||
| General meeting for 2025 | 2025-08-21 16:00 | 83.50 (-1.88%) | ||
| First quarter earnings conference call for 2026 | 2025-08-08 10:00 | 96.50 (+2.22%) |
Show
Entries
EQL Pharma AB Frequently Asked Questions
What is EQL Pharma AB(OSTO:EQL)'s stock price today?
The current price of OSTO:EQL is kr23.15. The 52 week high of OSTO:EQL is kr108.80 and 52 week low is kr21.35.
When is next earnings date of EQL Pharma AB(OSTO:EQL)?
The next earnings date of EQL Pharma AB(OSTO:EQL) is 2026-08-07 Est..
Does EQL Pharma AB(OSTO:EQL) pay dividends? If so, how much?
EQL Pharma AB(OSTO:EQL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on EQL Pharma AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers